His research focuses on the interplay between tumors and the immune system in early stages of cancer formation, and the development of novel immunotherapeutic treatment strategies with particular focus on melanoma as a model system. The FDA has approved multiple immune therapies recently (anti-CTLA-4, anti-PD1/PDL-1 and T-VEC) and he is now aiming to combine these treatments with conventional therapies that are known to modulate the immune system such as radiation therapy. He also has interest in studying the genetic determinants of response to immune therapies. His career is focused on developing immunotherapies for the treatment of cancer. He has been working on pre-clinical model and validating the relevance of the findings in clinical samples of patients treated with immunotherapies. His research is conducted within the Ludwig Collaborative and Swim Across America lab and in partnership with members of the Melanoma DMT and other MSK investigators with shared research interests. Dr. Merghoub has published over 100 per reviewed peer-reviewed papers and book-chapters. His research has also received funding from several federal agencies and philantopic organizations.
Taha Merghoub is involved in multiple organizations and some of them aim at helping Algerians both here in USA and in Algeria. He served in multiple associations (including AAF, AASA, ACA and the Harlem Children Society) that aim to help Algerian students, scientists and health professional.